Skip to content

US · RDY · DRUG MANUFACTURERS - SPECIALTY & GENERIC

Dr. Reddy's Laboratories Limited (RDY) intrinsic value and stock valuation

$14.89as of 2026-11-21 · Mkt cap 10.18B

Data updated · price as of 2026-11-21

OvervaluedIC value is 20–50% below the price. The exact IC value, upside and the fair-value band are available with Pro.
P/E
Pro
P/B
Pro
P/S
Pro

Price history

Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.

Dr. Reddy's Laboratories Limited DCF and intrinsic value

InvestorsCraft values RDY with the Chepakovich two-stage DCF model — currently rated overvalued. How the model works · Run your own DCF prefilled from RDY’s statements →

Dr. Reddy's Laboratories Limited Graham Number

Graham Number: $738.91d — the price is at or below the Graham Number. Formula √(22.5 × EPS × BVPS) using the latest diluted EPS and book value per share. Guide · Calculator →

Healthcare · Drug Manufacturers - Specialty & Generic Hyderabad, TS 500034 drreddys.com

How the business is doing

Fiscal 2012–2026, USD

Revenue
$353.5B+168% 5y CAGRd
20122026
Net income
$45.1B+186.8% 5y CAGRd
20122026
Free cash flow
$32.1B+6.8% 5y CAGRd
20122026
Total equity
$372.9B+175.1% 5y CAGRd
20122026

Is it expensive?

Each multiple against its own 15-year range, or against peers where no history is available

P/E
Pro
with Pro
P/B
Pro
with Pro
P/S
Pro
with Pro
EV/EBITDA
Pro
with Pro
P/EG
Pro
with Pro
P/TBV
Pro
with Pro

Peers

Same-industry companies, ranked by market cap

Peer comparison

The peer comparison table is shown only to users with a Pro subscription.

Financials

Statements by fiscal year

Fiscal 2012–2026, USD
20262025202420232022
Revenue$353.5B$325.5B$279.2B$245.9B$214.4B
Operating income$48.9B$71.8B$67.7B$57.1B$29.5B
Net income$45.1B$56.5B$55.7B$45.1B$23.6B
EPSd$54.1M$67.8M$66.8M$54.2M$28.3M
Operating cash flow$56.6B$46.4B$45.4B$58.9B$28.1B
Capital expenditure-$-24.54B-$-34.4B-$-27.44B-$-18.87B-$-19.05B
Free cash flow$32.1B$12B$18B$40B$9.06B
Total assets$567.9B$493B$387.5B$321.9B$292.8B
Total debt$75.8B$46.8B$20B$13.5B$33.8B
Net debt$60.7B$32.1B$12.9B$7.69B$19B
Total equity$372.9B$337.2B$280.6B$231B$190.5B
Cash and short-term investments$86.1B$57.9B$81.5B$61.8B$44.4B
Income statement
20262025202420232022
Revenue$353.5B$325.5B$279.2B$245.9B$214.4B
Cost of revenue$167B$135.1B$115.6B$106.5B$100.6B
Gross profit$186.5B$190.4B$163.6B$139.3B$113.8B
Research and development expenses$25.3B$27.4B$22.9B$19.4B$17.5B
Selling, general and administrative expenses$112.3B$93.9B$77.2B$68B$62.1B
Other expenses$0.00-$-2.67B-$-4.2B-$-5.21B$4.8B
Operating expenses$137.7B$118.6B$95.9B$82.2B$84.4B
Cost and expenses$304.6B$253.7B$211.4B$188.7B$184.9B
Interest income$8.28B$2.68B$2.28B$1.18B$965M
Interest expense$3.93B$2.83B$1.71B$1.43B$958M
Depreciation and amortization$21.7B$17.1B$14.8B$12.6B$11.8B
Ebitda$83.3B$96.7B$88.4B$74.4B$45.1B
Operating income$48.9B$71.8B$67.7B$57.1B$29.5B
Total other income/expenses, net$8.81B$4.94B$4.14B$3.22B$2.82B
Income before tax$57.7B$76.8B$71.9B$60.4B$32.3B
Income tax expense$13B$19.5B$16.2B$15.3B$8.73B
Net income$45.1B$56.5B$55.7B$45.1B$23.6B
Weighted average shares outstanding$832.4M$833.3M$833.5M$830.2M$829.4M
Weighted average diluted shares outstanding$833.3M$834.3M$833.5M$831.9M$831.7M
Balance sheet
20262025202420232022
Cash and short-term investments$86.1B$57.9B$81.5B$61.8B$44.4B
Net receivables$99.2B$109.8B$95.3B$83.2B$80.3B
Inventory$75B$71.1B$63.6B$48.7B$50.9B
Total current assets$296B$250.1B$248B$204.3B$181.9B
Property, plant and equipment, net$113.6B$97.8B$76.9B$66.5B$62.2B
Goodwill and intangible assets$115.6B$108.6B$41.2B$35.1B$31.7B
Long-term investments$16B$15.2B$5.26B$5.36B$7.99B
Total non-current assets$271.9B$242.9B$139.5B$117.6B$111B
Total assets$567.9B$493B$387.5B$321.9B$292.8B
Accounts payable$32.7B$20.1B$21.5B$17.9B$16B
Short-term debt$63.8B$38.9B$14B$12.2B$28.1B
Deferred revenue$0.00$1.98B$1.44B$1.98B$2.58B
Total current liabilities$164.2B$130.4B$96B$85.8B$94B
Long-term debt$12B$7.86B$5.99B$1.28B$5.75B
Deferred revenue, non-current$0.00$1.16B$1.19B$1.56B$1.6B
Total non-current liabilities$30.7B$25.4B$10.9B$5.02B$8.29B
Capital lease obligations$0.00$4.92B$3.5B$2.28B$2.96B
Total liabilities$195B$155.8B$107B$90.9B$102.3B
Common stock$818.5M$834M$834M$833M$832M
Retained earnings$345B$315.8B$265.3B$215.6B$175.7B
Accumulated other comprehensive income (loss)$10.5B$3.98B$653M$886M$755M
Total equity$372.9B$337.2B$280.6B$231B$190.5B
Total investments$87.1B$58.5B$79.6B$61.4B$37.5B
Total debt$75.8B$46.8B$20B$13.5B$33.8B
Net debt$60.7B$32.1B$12.9B$7.69B$19B
Cash flow statement
20262025202420232022
Net income$45.1B$57.2B$55.7B$45.1B$23.6B
Depreciation and amortization$21.7B$17.1B$14.8B$12.6B$11.8B
Stock-based compensation$0.00$424M$407M$397M$592M
Change in working capital-$-12.24B-$-29.99B-$-20.18B-$-7.86B-$-13.91B
Accounts receivable-$-7.07B-$-10.28B-$-8.05B-$-5.75B-$-17.01B
Inventory-$-9.05B-$-12.75B-$-18.45B-$-2.65B-$-5.33B
Accounts payable$2.94B$0.00$0.00$0.00$17B
Net cash provided by operating activities$56.6B$46.4B$45.4B$58.9B$28.1B
Investments in property, plant and equipment-$-40.43B-$-27.5B-$-16.4B-$-11.32B-$-19.05B
Acquisitions, net-$-2.99B-$-53.41B-$-12M$0.00-$-326M
Net cash used for investing activities-$-70.53B-$-58.08B-$-40.28B-$-41.37B-$-26.39B
Common stock issued$417.7M$193M$805M$368M$334M
Common stock repurchased$0.00-$-1.39B$0.00$0.00$0.00
Dividends paid-$-7.01B-$-6.66B-$-6.65B-$-4.98B-$-4.15B
Net cash used for financing activities$13.4B$18.9B-$-3.76B-$-26.86B-$-2.42B
Net change in cash-$-875.84M$7.49B$1.33B-$-9.07B$32M
Cash at end of period$15.1B$14.6B$7.11B$5.78B$14.9B
Operating cash flow$56.6B$46.4B$45.4B$58.9B$28.1B
Capital expenditure-$-24.54B-$-34.4B-$-27.44B-$-18.87B-$-19.05B
Free cash flow$32.1B$12B$18B$40B$9.06B
USD millions

Line items

    USD millions

    Line items

      USD millions

      Line items

        About Dr. Reddy's Laboratories Limited

        Dr. Reddy's Laboratories Limited, alongside its associated companies, functions as a holistic pharmaceutical entity with a global footprint. Its business operations are divided into several key divisions. The Global Generics segment is responsible for the manufacturing and sale of both prescription and over-the-counter finished pharmaceutical products. These offerings are available either under a proprietary brand or as generic formulations that are therapeutically identical to their branded equivalents. This segment also includes the company's biologics ventures. The Pharmaceutical Services and Active Ingredients (PSAI) division focuses on producing and distributing active pharmaceutical ingredients (APIs) and chemical intermediates, which serve as crucial building blocks for final drug products. Additionally, PSAI provides contract research services and produces custom-specified APIs and steroids for clients. The Proprietary Products segment is dedicated to the research and advancement of unique pharmaceutical formulations. The Others segment is actively involved in developing treatments, primarily for oncology (cancer) and inflammatory conditions. Dr. Reddy's addresses a broad spectrum of therapeutic areas, including gastrointestinal issues, cardiovascular health, diabetes, dermatological concerns, cancer, respiratory diseases, oral health, urological disorders, and nephrological conditions. The company has also established a partnership with Curis, Inc., centered on the discovery, development, and commercialization of small molecule antagonists designed for immuno-oncology and precision oncology targets. Founded in 1984, Dr. Reddy's Laboratories Limited maintains its principal office in Hyderabad, India.

        CEO
        Erez Israeli
        Employees
        27.53K
        Beta
        0.25

        Explore

        Frequently asked questions

        What is the intrinsic value of Dr. Reddy's Laboratories Limited (RDY)?

        Dr. Reddy's Laboratories Limited (RDY) is currently overvalued based on the InvestorsCraft IC model — IC value is 20–50% below the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.

        Is RDY undervalued?

        RDY trades at a price of $14.89 (Nov 21, 2026): overvalued — IC value is 20–50% below the price.

        How is the intrinsic value calculated?

        InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.

        How often is this page updated?

        Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.

        Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.